Browse the evidence

Baseline body mass index (BMI), glycated haemoglobin (HbA1c), and triglyceride levels can accurately predict future glycaemic control trajectories (stable, improved, or deteriorated) in patients with newly diagnosed type 2 diabetes.

If you have been newly diagnosed with type 2 diabetes, your doctor can use three simple numbers from your initial blood work—your BMI, your HbA1c, and your triglycerides—to predict how your blood sugar will likely behave over the next few years. This helps them decide whether you need frequent check-ups or if standard care is sufficient, allowing for more personalized management of your condition.

Low carbohydrate diets facilitate remission of Type 2 diabetes for some individuals, primarily through reducing hepatic and pancreatic fat storage and restoring beta-cell function.

For some people with Type 2 Diabetes, adopting a low carbohydrate diet can lead to remission. This is achieved by reducing fat in the liver and pancreas, which allows beta-cells to function better. While not guaranteed for everyone (especially those on insulin), it is a viable goal to discuss with your healthcare provider.

Three months of supervised moderate-intensity physical exercise attenuates adipose tissue inflammation (decreased IL-6 and TNF-α) in obese adults, regardless of diabetes status, though it differentially modulates Heat Shock Protein 60 (HSP60) expression based on diabetic status.

Engage in 40 minutes of moderate exercise (keeping heart rate at 65-80% of max) three times a week. This specific protocol has been shown to reduce inflammation in fat tissue for obese individuals, whether they have diabetes or not. Supervision is recommended to ensure safety and correct intensity.

Gut peptides (specifically GLP-1 and GIP) modulate hedonic feeding and reward-seeking behavior, extending beyond homeostatic satiety, which provides a mechanism for the significant weight loss observed with GLP-1/GIP receptor agonists.

Your brain's reward system for food is biologically regulated by hormones from your gut. Medications like GLP-1 agonists work not just by making you feel full, but by dampening the brain's reward response to food cues, making it easier to resist high-calorie foods without relying solely on willpower.

Leucine acts as the primary trigger for muscle protein synthesis by activating the mTORC1 pathway, and increasing leucine content in lower-quality proteins can restore the anabolic response in older adults.

Ensure your meals contain enough leucine, the 'trigger' for muscle building. High-quality proteins like whey, eggs, and meat are naturally rich in leucine. If you rely on plant proteins or lower-quality sources, you may need to consume larger portions or combine them to get enough leucine, especially as you age.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) reduce systemic and tissue inflammation through mechanisms that are partially independent of weight loss and metabolic improvements.

GLP-1 medications like semaglutide and liraglutide offer health benefits beyond just weight loss. They directly reduce inflammation in your body, which helps protect your heart, kidneys, and joints. This happens through direct actions on your immune system and nerves, not just by making you thinner. Even if your weight stays the same, you may still receive these protective anti-inflammatory effects.

Medication reduction is a prominent and immediate benefit of VLCKD, often occurring before significant weight loss or A1c improvement is sustained, and may blunt the observed A1c response in long-term studies.

If you have Type 2 Diabetes, starting a very low-carb diet (<50g carbs/day) often leads to a rapid need to reduce or stop diabetes medications, sometimes before you lose much weight. This is a good thing, but it requires close monitoring by your doctor to avoid hypoglycemia. Do not stop your medications on your own; work with your provider to adjust doses as your blood sugar improves.

GLP1/Estrogen (GLP1/E) multi-agonist therapy provides superior metabolic improvement in PCOS models compared to GLP1 monotherapy, dual/triple agonists, and metformin, achieving significant weight loss, fat mass reduction, and improved insulin sensitivity without gastrointestinal distress.

For individuals with PCOS and metabolic issues, GLP1/Estrogen multi-agonist therapy appears to be a highly effective treatment option, significantly outperforming standard care like metformin in reducing weight, fat, and improving insulin sensitivity. While currently studied in mice, this suggests a promising future therapeutic avenue for managing PCOS-related metabolic complications.

GLP-1 receptor agonists (GLP-1RAs) including semaglutide 2.4 mg and tirzepatide induce significant weight loss (12-20%) and improve metabolic comorbidities, but discontinuation of therapy leads to rapid weight regain, indicating that obesity treatment with these agents requires long-term or lifelong administration.

GLP-1 medications like semaglutide (2.4 mg weekly) and tirzepatide are highly effective for weight loss, achieving 12-20% body weight reduction in clinical trials. However, these drugs treat obesity as a chronic condition; stopping treatment typically leads to rapid weight regain. Therefore, successful long-term management likely requires continuous, lifelong therapy. Side effects like nausea are common but manageable through slow dose escalation. Oral versions are emerging to address injection aversion.

Visceral Adipose Tissue (VAT) is a stronger predictor of metabolic syndrome and cardiovascular disease risk than total fat mass or BMI, particularly in Asian populations where VAT accumulation occurs at lower BMI thresholds.

Focus on reducing visceral fat, not just total weight. If you are Asian or older, your BMI might be 'normal' while your visceral fat is high. Use waist circumference or body composition scans to monitor VAT. Reducing VAT through exercise and diet is critical for lowering metabolic syndrome risk.

Psychogenic factors, particularly stress and PTSD, are decisive in the development of obesity through mechanisms involving high cortisol and sympathetic overactivity.

If you struggle with stress or PTSD, recognize that these mental health challenges can biologically drive weight gain through cortisol. Addressing mental health through therapy or stress management is a critical part of obesity treatment.

High baseline insulin secretion predicts greater long-term weight gain, particularly when consuming high-glycemic-index diets, supporting the carbohydrate-insulin model of obesity pathogenesis.

If you have high insulin levels, focus on reducing the glycemic load of your diet. High-glycemic foods may trigger excessive insulin secretion, promoting fat storage and weight gain, especially in those predisposed to insulin resistance.

In overweight and obese women, twice-daily exenatide treatment yields long-term weight loss outcomes similar to a hypocaloric diet with matched placebo injections, with no significant difference in the proportion of super responders (≥10% weight loss).

For overweight women, twice-daily exenatide does not guarantee better long-term weight loss than a strict hypocaloric diet alone. In fact, the study showed similar rates of significant weight loss (≥10%) between the drug and diet groups. The high response in the diet group suggests that the ritual of pre-meal injections may aid adherence. Patients should weigh the burden of daily injections against the potential benefit, as diet alone can be highly effective for early responders.

In Type 2 Diabetes, the adoption of newer glucose-lowering medications (GLP-1 agonists and SGLT2 inhibitors) is associated with a significant decline in fracture incidence rates, particularly in men and women under 50 and over 70.

If you have Type 2 Diabetes, discuss with your doctor whether your current medication increases your fracture risk. The data suggests that switching to newer classes of drugs, specifically GLP-1 agonists or SGLT2 inhibitors, is associated with a significant reduction in fracture rates compared to older medications like sulfonylureas.

GLP-1 receptor agonists (specifically liraglutide and semaglutide) improve histological features of NASH and achieve resolution of NASH without worsening fibrosis in adults with or without type 2 diabetes.

If you have NASH, GLP-1 agonists like semaglutide or liraglutide are proven to improve liver health, potentially resolving the disease without worsening scarring. They are taken as injections (daily or weekly). While they can cause nausea, the liver benefits are substantial, especially if you have type 2 diabetes or obesity. Consult your doctor for dosing.

SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce liver fat content in patients with NAFLD, as assessed by MRI-based techniques.

SGLT2 inhibitors like empagliflozin or dapagliflozin reduce liver fat in people with type 2 diabetes and fatty liver. They are oral medications taken daily. They can increase the risk of genital infections, so good hygiene is important. They also help with weight and blood sugar.

Physical exercise provides cardiovascular and mental health benefits independent of weight loss, justifying its inclusion in obesity treatment even when pharmacological weight loss is significant.

Even if your medication helps you lose weight, keep exercising. It protects your heart and mood in ways that weight loss alone might not. Focus on brisk walking and basic strength exercises rather than intense workouts.

Industrial trans fats are harmful and should be avoided, while natural trans fats (from ruminants) are beneficial and may protect against heart disease.

Avoid processed foods with 'partially hydrogenated oils' (industrial trans fats). However, do not avoid natural trans fats found in butter and meat from grass-fed animals, as they may actually protect your heart.

Gastric bypass results in large and long-lasting weight loss (25-27% total body weight loss at 12-15 years) and remission of obesity-related conditions, making it suitable for patients with BMI 35-50 kg/m2, especially with type 2 diabetes or reflux.

Gastric bypass is a highly effective surgical option for patients with BMI 35-50, especially those with type 2 diabetes or reflux. It leads to large, long-lasting weight loss (25-27% at 12-15 years) and remission of obesity-related conditions.

Tirzepatide (15 mg) produces a greater improvement in insulin sensitivity per unit of weight loss compared to semaglutide (1 mg) in patients with type 2 diabetes, suggesting mechanisms beyond simple adiposity reduction.

If you are treating type 2 diabetes with GLP-1 based therapies, tirzepatide (15 mg) appears to offer superior improvements in how your body uses insulin for every pound lost, compared to semaglutide (1 mg). This suggests tirzepatide works through additional hormonal pathways (GIP/GLP-1) beyond just reducing fat mass. For patients prioritizing metabolic health improvements alongside weight loss, this distinction may be clinically relevant.

GLP-1 receptor agonists (e.g., Liraglutide) reduce appetite and improve glucose tolerance by stimulating anorexigenic POMC/CART neurons and suppressing orexigenic AgRP/NPY neurons via cAMP and GABA-dependent signaling pathways.

GLP-1 based therapies work by targeting the brain's hunger centers (POMC/CART) to reduce appetite and improve blood sugar control. This suggests that obesity management can involve pharmacological support of natural hormonal signals, rather than relying solely on behavioral changes.

Fermented dairy products (cheese, yogurt) and probiotics are associated with a lower risk of cardiovascular disease (CVD) and type 2 diabetes, independent of saturated fat content, whereas non-fermented low-fat milk may be associated with higher diabetes risk.

Prioritize fermented dairy products like cheese and yogurt over non-fermented low-fat milk for metabolic health. These foods are associated with a lower risk of cardiovascular disease and type 2 diabetes. The fermentation process and specific fatty acid profiles in dairy appear to offer protective benefits that contradict the general fear of saturated fats.

Testosterone therapy in transgender men leads to increased lean mass and visceral adiposity, while estrogen therapy in transgender women leads to decreased lean mass and increased fat mass, confirming the causal role of sex steroids in body composition.

If you are undergoing gender-affirming hormone therapy, expect your body composition to shift towards your new hormonal profile. Trans men will likely gain muscle and visceral fat; trans women will likely lose muscle and gain subcutaneous fat. This is a direct result of the hormones, not lifestyle failure.

Menopause triggers a shift in fat distribution from protective subcutaneous tissue to harmful visceral adipose tissue due to declining estrogen levels, increasing the risk of metabolic disease.

As you approach menopause, your body will naturally start storing more fat around your organs (visceral) rather than your hips and thighs. This increases metabolic risk. Hormone replacement therapy can partially reverse this shift, but lifestyle management of visceral fat becomes critical.